Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plethico Pharmaceuticals to acquire Natrol
<p>The acquisition will be effected by an initial general tender offer by a wholly owned subsidiary of Plethico for all of the outstanding shares of Natrol’s common stock,
<p>The acquisition will be effected by an initial general tender offer by a wholly owned subsidiary of Plethico for all of the outstanding shares of Natrol’s common stock,
In the initial dose escalation Phase of the trial, 15 patients were treated sequentially in four dose cohorts with escalating doses of radiolabeled TM-601. Because no dose-limiting toxicities
This study will be a randomized, examiner-blinded, parallel design trial comparing three different doses of PAC-113 to Nystatin, a topical mouth rinse treatment for oral candidiasis. The study
The objectives of the study were to define the safety profile and maximum tolerated dose of RAV12, to define the pharmacokinetics and describe preliminary efficacy. Treatment with RAV12
This new study is expected to provide the first assessment of TPI 1020’s potential activity in COPD. The trial is a 6-week, multi-center, double blind, placebo and active-controlled
Each study will evaluate the efficacy of ofatumumab in reducing the clinical signs and symptoms in RA patients after a single course of ofatumumab and are comprised of
The US District Court of California has issued a ruling in favor of the company, affirming that its intellectual property rights for the Microcyn technology are enforceable. In
The patent relates to the combined use of a cardiac marker of cell injury, such as Troponin I, with a marker of organ adaptation, such as brain natriuretic
The multi-year agreement broadens the scope of Covidien Imaging Solutions products available to MedAssets Supply Chain Systems customers nationwide. Under the agreement, which became effective on November 1,
The patent illustrates the company’s Morphodoma technology, a whole genome evolution platform that can enhance cells producing monoclonal antibodies to yield daughter cells producing antibodies with enhanced pharmacologic